Neurogene Inc.
For the period ended Dec 31, 2025. Filed Mar 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 24, 2026
NGNE$26.00+2.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
Consolidated Statements of Operations
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue under licensing agreements | $— | $925 |
| Operating expenses: | ||
| Research and development expenses | 75,011 | 60,917 |
| General and administrative expenses | 28,317 | 22,613 |
| Total operating expenses | 103,328 | 83,530 |
| Loss from operations | (103,328) | (82,605) |
| Other income (expense): | ||
| Interest income | 11,547 | 8,467 |
| Interest expense | (5) | (12) |
| Other income | 1,665 | 574 |
| Other expense | (230) | (1,568) |
| Net loss | $(90,351) | $(75,144) |
| Per share information: | |||
|---|---|---|---|
| Net loss per share, basic and diluted | $(4.24) | $(4.28) | |
| Weighted-average shares of common stock outstanding, basic and diluted | 21,326,283 | 17,567,082 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.